Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency

  1. Anna Polesskaya1,2,5,
  2. Sylvain Cuvellier1,2,
  3. Irina Naguibneva1,2,
  4. Arnaud Duquet1,4,
  5. Eric G. Moss3, and
  6. Annick Harel-Bellan1,2
  1. 1 Centre National de la Recherche Scientifique (CNRS) FRE 2944, Institut André Lwoff, Villejuif F-94801, France;
  2. 2 Université Paris-Sud, Villejuif F-94801, France;
  3. 3 Department of Molecular Biology, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey 08084, USA

Abstract

Lin-28 is a highly conserved, RNA-binding, microRNA-regulated protein that is involved in regulation of developmental timing in Caenorhabditis elegans. In mammals, Lin-28 is stage-specifically expressed in embryonic muscle, neurons, and epithelia, as well as in embryonic carcinoma cells, but is suppressed in most adult tissues, with the notable exception of skeletal and cardiac muscle. The specific function and mechanism of action of Lin-28 are not well understood. Here we used loss-of-function and gain-of-function assays in cultured myoblasts to show that expression of Lin-28 is essential for skeletal muscle differentiation in mice. In order to elucidate the specific function of Lin-28, we used a combination of biochemical and functional assays, which revealed that, in differentiating myoblasts, Lin-28 binds to the polysomes and increases the efficiency of protein synthesis. An important target of Lin-28 is IGF-2, a crucial growth and differentiation factor for muscle tissue. Interaction of Lin-28 with translation initiation complexes in skeletal myoblasts and in the embryonic carcinoma cell line P19 was confirmed by localization of Lin-28 to the stress granules, temporary structures that contain stalled mRNA–protein translation complexes. Our results unravel novel mechanisms of translational regulation in skeletal muscle and suggest that Lin-28 performs the role of “translational enhancer” in embryonic and adult cells and tissues.

Keywords

Footnotes

  • 4 Present address: Department of Genetic Medicine and Development, University of Geneva Medical School, 1, rue Michel Servet, CH-1211, Geneva 4, Switzerland.

  • 5 Corresponding author.

    5 E-MAIL apoles{at}vjf.cnrs.fr; FAX 33-1-49583307.

  • Supplemental material is available at http://www.genesdev.org.

  • Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.415007

    • Received October 18, 2006.
    • Accepted March 7, 2007.
| Table of Contents

Life Science Alliance